Serum Biomarkers in Parkinson's Disease at Different Stages

NCT ID: NCT05769699

Last Updated: 2023-03-15

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

200 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-02-10

Study Completion Date

2027-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

* Determine clinical characteristics of parkinsonian patients in various stages of disease;
* Measure peripheral neurodegeneration, synaptic, and inflammation biomarkers in a population of parkinsonian patients at various stages of disease.
* Measure vesicular neurodegeneration, synaptic and inflammation biomarkers

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Parkinson Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Biomarkers

Group Type EXPERIMENTAL

blood sample

Intervention Type PROCEDURE

blood sample

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

blood sample

blood sample

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients diagnosed with idiopathic PD according to Movement Disorders Society (MDS) criteria;
* Age: 18-80 years;
* Signature of informed consent to participate in this study

Exclusion Criteria

* Women pregnant
* Inflammatory or autoimmune diseases
Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Flavia Torlizzi

Roma, , Italy

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Italy

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Giulia Di Lazzaro, MD

Role: CONTACT

0630154303

Flavia Torlizzi

Role: CONTACT

0630156433

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Flavia Torlizzi

Role: primary

+390630156433

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

4687

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Measuring Parkinson's Disease Progression
NCT03205956 COMPLETED PHASE1
Biomarkers in Neural Disorders
NCT02761707 COMPLETED